AmWeb: A novel interactive web tool for antimicrobial resistance surveillance, applicable to both community and hospital patients

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 10, 2013, Pages 2406-2413

  Ironmonger, Dean ^a   Edeghere, Obaghe ^a   Gossain, Savita ^b   Bains, Amardeep ^a   Hawkey, Peter M ^b,c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antibiotics; Health informatics; Microbiology

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CARBAPENEMASE; IMIPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; HEALTH CARE QUALITY; HOSPITAL PATIENT; HUMAN; INFORMATION PROCESSING; KLEBSIELLA PNEUMONIAE; MEDICAL INFORMATICS; PATIENT CARE; PRACTICE GUIDELINE; UNITED KINGDOM;

ANTIBIOTICS; HEALTH INFORMATICS; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENGLAND; EPIDEMIOLOGICAL MONITORING; HUMANS; INTERNET;

EID: 84888786930     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt181     Document Type: Article

References (31)

1. World Health Organization. WHO Global Strategy for Containment of Antimicrobial Resistance. http://whqlibdoc.who.int/hq/2001/WHO_CDS_ CSR_DRS_2001.2.pdf (23 March 2013, date last accessed).
2. European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe 2011. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). http://ecdc. europa.eu/en/publications/Publications/antimicrobial-resistance-surveillanceeurope-2011.pdf (15 March 2013, date last accessed).
3. EuropeanCentre for Disease PreventionandControl (ECDC)andEuropean Medicines Agency (EMEA). Technical Report-The Bacterial Challenge: Time to React. http://www.ecdc.europa.eu/en/publications/Publications/0909_ TER_The_Bacterial_Challenge_Time_to_React.pdf (12 March 2013, date last accessed).
4. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008; 6: 751-63.
5. Commission to the European Parliament and the Council. Action Plan against the Rising Threats from Antimicrobial Resistance. http://ec.europa. eu/dgs/health_consumer/docs/communication_amr_2011_748_en.pdf (25 March 2013, date last accessed).
6. Bax R, Bywater R, Cornaglia G et al. Surveillance of antimicrobial resistance-what, how and whither? Clin Microbiol Infect 2001; 7: 316-25.
7. Felmingham D. The need for antimicrobial resistance surveillance. J Antimicrob Chemother 2002; 50 Suppl S1: 1-7.
8. Hayward AC, Goldsmith K, Johnson AM. Report of the Specialist Advisory Committee on Antimicrobial Resistance (SACAR) Surveillance Subgroup. J Antimicrob Chemother 2007; 60 Suppl 1: i33-42.
9. Heginbothom ML, Magee JT, Bell JL et al. Laboratory testing policies and their effects on routine surveillance of community antimicrobial resistance. J Antimicrob Chemother 2004; 53: 1010-7.
10. House of Lords Select Committee on Science and Technology. Seventh Report: Resistance to Antibiotics and Other Antimicrobial Agents. http://www.parliament.the-stationery-office.co.uk/pa/ld199798/ldselect/ ldsctech/081vii/st0702.htm (23 March 2013, date last accessed).
11. Kahlmeter G, Brown DF. Resistance surveillance studies-comparability of results and quality assurance of methods. J Antimicrob Chemother 2002; 50: 775-7.
12. O'Brien TF, Stelling J. Integrated multilevel surveillance of the world's infecting microbes and their resistance to antimicrobial agents. Clin Microbiol Rev 2011; 24: 281-95.
13. Schrag SJ, Zell ER, Schuchat A et al. Sentinel surveillance: a reliableway to track antibiotic resistance in communities? Emerg Infect Dis 2002; 8: 496-502.
14. Stelling JM, O'Brien TF. Surveillance of antimicrobial resistance: the WHONETprogram. Clin Infect Dis 1997; 24 Suppl 1: S157-68.
15. Lovis C, Colaert D, Stroetmann VN. DebugIT for patient safety-improving the treatment with antibiotics through multimedia data mining of heterogeneous clinical data. Stud Health Technol Inform 2008; 136: 641-6.
16. Grundmann H, Klugman KP, Walsh T et al. A framework for global surveillance of antibiotic resistance. Drug Resist Updat 2011; 14: 79-87.
17. Centers for Disease Control and Prevention. Addressing emerging infectious disease threats: a prevention strategy for the United States (Executive Summary). http://www.cdc.gov/mmwr/PDF/rr/rr4305.pdf (2 April 2013, date last accessed).
18. White AR. The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: a successful collaborative model. J Antimicrob Chemother 2008; 62 Suppl 2: ii3-14.
19. Health Protection Agency. Laboratory Reporting to the Health Protection Agency-Guide for Diagnostic Laboratories. http://www.hpa.org.uk/webc/ HPAwebFile/HPAweb_C/1194947381307 (15 February 2013, date last accessed).
20. NHS Connecting for Health. NHS Organisation Data Service. http://www. connectingforhealth.nhs.uk/systemsandservices/data/ods (15 February 2013, date last accessed).
21. Andrews JM, Howe RA. BSAC standardized disc susceptibility testing method (version 10). J Antimicrob Chemother 2011; 66: 2726-57.
22. Howe RA, Andrews JM. BSAC standardized disc susceptibility testing method (version 11). J Antimicrob Chemother 2012; 67: 2783-4.
23. Robert Koch Institute. ARS German Antimicrobial Resistance Surveillance. http://ars.rki.de/ (20 February 2013, date last accessed).
24. Hombach M, Bloemberg GV, Bottger EC. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J Antimicrob Chemother 2012; 67: 622-32.
25. National Committee for Clinical Laboratory Standards. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline. http://130.185.73.107:60/2/M39-A.pdf (22 March 2013, date last accessed).
26. Morris AK, Masterton RG. Antibiotic resistance surveillance: action for international studies. J Antimicrob Chemother 2002; 49: 7-10.
27. Magee JT. Effects of duplicate and screening isolates on surveillance of community and hospital antibiotic resistance. J Antimicrob Chemother 2004; 54: 155-62.
28. Gupta K, Sahm DF, Mayfield D et al. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 2001; 33: 89-94.
29. Howard AJ, Magee JT, Fitzgerald KA et al. Factors associated with antibiotic resistance in coliform organisms from community urinary tract infection inWales. J Antimicrob Chemother 2001; 47: 305-13.
30. Stelling J, Yih WK, Galas M et al. Automated use ofWHONETandSaTScan to detect outbreaks of Shigella spp. using antimicrobial resistance phenotypes. Epidemiol Infect 2010; 138: 873-83.
31. UK Government Legislation. The Health Protection (Notification) Regulations 2010. http://www.legislation.gov.uk/uksi/2010/659/pdfs/uksi_20100659_en.pdf (15 March 2013, date last accessed).